834
Participants
Start Date
July 31, 2007
Primary Completion Date
July 31, 2011
Study Completion Date
June 30, 2012
Gemcitabine plus TS-1
Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
TS-1
TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
Gemcitabine
Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
National Taiwan University Hospital, No.7, Chung San South Road, Taipei
Mackay Memorial Hospital, Taipei, No.92, Sec. 2, Zhongshan N. Rd., Taipei
Taipei Veterans General Hospital, No.201, Sec. 2, Shih-Pai Road, Taipei
Chang Gung Memorial Hospital, Lonkou, No.5, Fu-Hsing Saint Kuei Shan Hsiang, Taoyuan Hsien
China Medical University Hospital, No.2, Yuh-Der Rd.,Taichung
Changhua Christian Hospital, No.135, Nanxiao St., Changhua
National Cheng Kung University Hospital, No.138, Sheng Li Road,Tainan
Chi Mei Medical Center, No.901, Chung Hwa Rd., Yong Kang City, Tainan
Chi Mei Medical Center Liou Ying Campus, No.201, Taikang Village, Liou Ying Township, Tainan
Chung-Ho Memorial Hospital, Kaohsiung Medical University, No.100, Tzyou 1st Rd., Kaohsiung
Chang Gung Memorial Hospital, Kaohsiung, No.123, Ta-Pei Rd., Niao-Sung Hsiang, Kaohsiung Hsien
National Cancer Center Hospital, Tokyo
TTY Biopharm
INDUSTRY
Taiho Pharmaceutical Co., Ltd.
INDUSTRY